Inxmed Biotechnology (Nanjing) Co , Ltd , a global innovative drug research and development company focusing on breakthroughs in solid tumor drug resistance，announced that it has completed B+ financing round!

Heluoxintu completes tens of millions of yuan in Angel Round financing，used for the construction of a cell therapy platform based on induced pluripotent stem cells (iPSCs)!

Jiangsu VCARE’s Series A financing has come to a close, with a total financing of nearly US$60 million This round of financing will continue to be supported by SDIC Investment Promotion, and jointly invested with Changjiang Industrial Investment

ExoRNABio announced the completion of an angel round of financing The first phase of financing amounted to tens of millions of yuan